VERDOT Announces Plans for Construction of New Headquarters and Manufacturing Facility in Riom France

• 4200 square-meter headquarter and manufacturing facility in Riom, France
• Consolidation of existing facilities with 150% additional manufacturing capacity
• Facility will be operational by early 2026

VERDOT® today announced that it has completed a transaction to purchase 11,000 square-meters (2.7 acres) of land in the Biopole Clermont-Limagne Life Science Technology Park in Riom, France, which is planned to be the site of an approximately 4200 square-meter (45,000 square-feet) headquarters and manufacturing facility.  Construction is expected to begin in the first quarter of 2025.

The new site is anticipated to open early 2026. It will consolidate their existing two facilities, create a Center of Excellence for bioprocessing manufacturing, research and development, and an applications laboratory.  The Company expects that the new facility will result in the creation of approximately 50-75 new jobs in the local area.

The state-of-the-art facility will utilize the latest technologies to design, fabricate and assemble bioprocessing purification solutions as well as create 150% additional manufacturing capacity for the company.

The new manufacturing site will be energy efficient, self-sufficient in electricity generation, equipped with water collection and recycling systems, and compliant with all environmental and regulatory standards. This new site will contribute to continuing the ambitious company’s decarbonization trajectory, initiated over 10 years ago.

Charles Ruban, CEO of VERDOT commented, “we are excited to begin construction of our new facility.  The new VERDOT facility will add significant manufacturing capacity, allowing us to further reduce lead times for tailored and standard purification technologies to meet the growing demand of our biopharmaceutical customers worldwide.  The consolidation of our existing facilities will create operational and R&D efficiencies that will enhance our engineering capabilities and fuel innovation, while further reducing our carbon footprint.”

About VERDOT

VERDOT®, established in 1950 and headquartered in Riom, France, stands at the forefront of downstream bioprocessing technology. VERDOT focuses on innovative purification solutions for the biopharmaceutical industry, including chromatography columns, and custom and standardized chromatography and tangential flow filtration (TFF) systems. VERDOT systems and columns are employed in the purification, separation and concentration of biomolecules such as monoclonal antibodies, vaccines, viral vectors (e.g., AAV and lentivirus), and mRNA-based therapeutics.

VERDOT serves a diverse customer base, including research and development, early-stage biotech, biopharma, and contract development and manufacturing organizations (CDMOs) in all stages of the drug development workflow from exploration through the manufacturing of commercially available biologics. VERDOT’s tailored, high-quality purification technologies empower their customers to accelerate time-to-market of groundbreaking and cost-effective therapies.

For more information about VERDOT, visit www.verdot-biotechnologies.com

Imogen Quail, PR Manager, ramarketing imogen.quail@ramarketingpr.com